Fundraising Foxティーセルヌーヴォー㈱
Tokyo, JP · 1 known investors
Find your way into ティーセルヌーヴォー㈱
Sign up to see every warm intro you have to ティーセルヌーヴォー㈱
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ティーセルヌーヴォー㈱ team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
T Cell Nouveau develops Hybrid CAR-T cell therapies designed to treat solid tumors by enhancing immune system activation in suppressive tumor microenvironments. The clinical-stage biopharmaceutical company targets cancer patients and originated from research conducted at Mie University's Personalized Cancer Immunotherapy department.
Founders & leadership
Investors · 1
Frequently asked questions
- What does ティーセルヌーヴォー㈱ do?
- T Cell Nouveau develops Hybrid CAR-T cell therapies designed to treat solid tumors by enhancing immune system activation in suppressive tumor microenvironments. The clinical-stage biopharmaceutical company targets cancer patients and originated from research conducted at Mie University's Personalized Cancer Immunotherapy department.
- Who founded ティーセルヌーヴォー㈱?
- ティーセルヌーヴォー㈱ was founded by Hiroshi Shiku.
- Who are ティーセルヌーヴォー㈱'s investors?
- ティーセルヌーヴォー㈱'s investors include DBJ Capital.
- Where is ティーセルヌーヴォー㈱ headquartered?
- ティーセルヌーヴォー㈱ is headquartered in Tokyo, JP.